43 results about "Normal cell" patented technology

The application discloses a cell detection method and system based on deep learning and machine vision, which comprises the following steps: cutting a cervical liquid-based cell pathology digital image into a plurality of sub-images to form a sub-image set; inputting the sub-image set into a normal cell detection model and a lesion cell detection model respectively, and identifying normal cells and lesion cells and their categories; selecting an overlapping area of the normal cells and the lesion cells, and performing secondary classification on the overlapping area through a classification model; performing threshold segmentation on granulocytes in the cervical liquid-based cell pathology digital image to obtain all possible granulocyte targets, filtering to determine final granulocyte targets, and counting and determining the number of the granulocytes. The application solves the problem that the detection model in the prior art has poor detection effect due to the imbalance of normal cell and lesion cell categories, improves the accuracy of cell identification, and realizes accurate detection and identification of cervical liquid-based cells in combination with accurately identified granulocytes.

This application relates to a method, apparatus, and memory for detecting memory failures. The memory failure detection method performs error detection on read data from the memory array to identify failed cells. When repair triggering conditions are met, a repair operation is performed on the failed cell. The success of the repair is verified. If successful, the failed cell is marked as a normal memory cell and continues to be used. If not, redundant cells are used to replace the failed cell. Performing repair operations on failed cells can repair soft-failure cells, avoiding the replacement of a large number of normal cells by redundant cells, thus consuming redundant resources. This allows limited redundant cells to replace unrepairable hard-failure cells, improving the effective utilization rate of redundant cells and preventing redundant resources from being prematurely consumed by repairable soft-failure cells, thus delaying the depletion rate of redundant resources and extending the working life of the memory.

This invention discloses a nanoparticle-based drug delivery system, MPL@ICC, its synthesis method, and its applications. The MPL@ICC system consists of hollow, porous nano-MnO2, a hydrophilic targeting complex on its surface, and an acid-responsive drug, INH-CA, and a photosensitizer loaded internally. It possesses both targeted transport and controlled release capabilities against human hepatocellular carcinoma cells (HepG2), allowing it to accumulate within these cells and achieve photodynamic therapy (PDT) and free radical-induced immune killing within the tumor. Simultaneously, it directly kills tumor cells and transforms them from non-immunogenic to immunogenic, mediating an anti-tumor immune response and achieving immunogenic cell death (ICD). This overcomes the shortcomings of ICD-induced cancer treatment strategies, which often fail to produce strong and durable therapeutic effects, and does not induce normal cell apoptosis, thus possessing controllability, effectiveness, and safety.

The present invention describes novel drug-carrying nanoparticles called bionanocarriers capable of modulating the cellular redox system and targeting the cancerous tumor.Specifically, the invention relates to a nanomedicine strategy for combating cancerous tumor cells, a strategy that aims to target the tumor, and consists of providing quercetin-linked magnetite nanoparticles (Q): (MNPs Q), and 3,5-dimaleylbenzoic acid-linked magnetite nanoparticles (A3'5DMB): (MNPs A3'5DMB)M; both types of nanoparticles were subsequently encapsulated with chitosan (Qs) and O-carboxymethyl chitosan (O-CMQs), functionalized with 11-mercaptoundecanoic acid (MUDA), and finally the anti-ABCC3 antibody was attached to the polymer phase, which was used as a selective driver of the delivery process of the encapsulated nanoparticles, thus carrying out the construction of the bionanocarriers: BNC-1: MNPs-Q-Ab; BNC-2: MNPs-a3'5DMB-Ab.Its manufacturing method and the tests of its biological functionality, its stability, the degradation of the encapsulation for the tumor microenvironment, the controlled release profile of the drugs Q and A3'5DMB, selective cell uptake, intracellular localization, cytotoxic effect on steroids of hepatocellular carcinoma cells with altered redox balance and induction of apoptosis, as well as its safety on normal cells, are described.

The present application relates to the technical field of biological medicine, and more particularly to a multifunctional antibody K1932 binding human CD19, CD3 and Fc gamma R, wherein the multifunctional antibody is composed of a bivalent Fab fragment specifically recognizing CD19 on the surface of B lymphocyte, a bivalent single-chain antibody recognizing CD3 molecule on the surface of T lymphocyte, and a human immunoglobulin Fc domain binding with Fc receptor, wherein the single-chain antibody recognizing CD3 molecule is connected with the C-terminal of Fab light chain through a connecting peptide Linker1, and the heavy chain and the light chain of the CD3 single-chain antibody are connected by a flexible Linker2; the biological macromolecule with the three functional domains is a highly directional immunotherapy drug, which is suitable for injection administration, can guide T cells to attack CD19-positive B lymphocytes, and the Fc domain is combined with Fc gamma R, so that the in-vivo half-life of the biological macromolecule is adjusted and the unnecessary influence on normal cells is reduced.

Embodiments of the present application disclose a pan-cancer cell recognition model training method, device, equipment and storage medium. The method comprises selecting transcriptome test data of a plurality of preset cancer types according to a preset ratio of normal cells and malignant cells to construct an initial data set; obtaining a preset number of high variable genes in the transcriptome test data of the initial data set as training features to obtain a training set; based on a binary classification label, performing label annotation on the transcriptome test data in the training set to generate a binary classification label system test data set; taking the pre-training weight of a preset base model as an initialization parameter, mounting a binary classification head at the top layer of a transformer layer, and performing parameter fine-tuning on the preset base model based on the binary classification label system test data set to obtain a pan-cancer cell recognition model. The scheme of the embodiments of the present application can realize accurate identification of benign and malignant cells in pan-cancer single-cell transcriptome data.

Provided is a controllable RNAm6A demethylation editing system comprising a targeting element and an editing element. The targeting element comprises an inactivated Cas13 protein, and the editing element comprises a methyltransferase domain of FTO and / or ALKBH5. The editing system can specifically perform m6A demethylation editing in tumor cells without affecting the m6A demethylation regulation of normal cells. In addition, the editing system does not require additional light or chemical inducers, thereby eliminating the side effects of inducers on cells and organisms.

The present invention relates to a method for inspecting a short circuit of a battery and a method for processing a battery. The method for inspecting a short circuit of a battery comprises the steps of: preparing a battery in which a plurality of cells are aligned; applying a current to the battery in which the plurality of cells are aligned; measuring a change amount of a magnetic field around the plurality of cells in a direction in which the plurality of cells are aligned in the battery in which the plurality of cells are aligned; and determining a normal unit including a normal cell and a short circuit unit including a short circuited cell from among the plurality of cells, through the change amount of the magnetic field.

The invention relates to a triple-effect T cell adapter for targeting T cell lymphoma TRBC1. The invention discloses a TRBC1-targeted triple-effect T cell adapter which is composed of an Fc region, a hinge region, a first Fab arm and a second Fab arm, and a third targeting module is covalently connected to the C end of the Fc region to form a Y-shaped triple-head antibody. The first Fab arm and the second Fab arm are respectively combined with TRBC1 and CD3, and the third Fab arm is combined with CD28 or CD137, so that three functions of tumor recognition, T cell recruitment and co-stimulation amplification are integrated. The two polypeptide chains are heterodimerized through CH3 region button mutation, and correct assembly is ensured. The structure supports module interchange, programmable regulation and control of synergistic signals, significantly enhances TRBC1 positive T cell lymphoma killing, reduces toxicity to normal T cells, has high activity and a wide safety window, and is suitable for preparation of related drugs.

A memory device and a memory module are provided. The memory device can include a memory cell array including a normal cell region storing data, and an error detector configured to detect an error of the data, the error detector can include an error location information extractor configured to extract first error location information of a first error bit in first data read from the normal cell region in a first read operation, and extract second error location information of a second error bit in the first data read from the normal cell region in a second read operation, and an error location comparator configured to compare the first error location information with the second error location information, and output a signal based on a comparison result of the first error location information and the second error location information.

The application discloses application of a palmitoylation inhibitor in inducing macrophage apoptosis, belongs to the technical field of biological medicine, and particularly relates to a preparation method of a pharmaceutical composition, which comprises the following steps: mixing the palmitoylation inhibitor with a medical reagent to prepare the pharmaceutical composition; the palmitoylation inhibitor is 2-BP, and the use amount of the 2-BP is 0.0015-0.07 wt% of the medical reagent. The application utilizes the 2-BP to specifically up-regulate the expression of CPT1A in the macrophages in a pathological state, thereby selectively inducing the apoptosis of the macrophages, has a smaller influence on normal cells, and significantly improves a safety window of treatment. The pharmaceutical composition can effectively induce the apoptosis of the macrophages, reduce non-specific killing on normal cells, and treat diseases related to abnormal activation or accumulation of the macrophages.

A normal set of cells is characterized using flow cytometry. A centroid and radius are defined for a set of clusters in an n-dimensional space corresponding to a normal maturation for a cell lineage in the normal set of cells. A test set of cells is characterized using flow cytometry and the characterization is compared to the defined set of clusters. Support Vector Machine (SVM) subroutines are employed to identify reference populations of interest by generating multidimensional boundary definitions. These boundary definitions may be used to identify reference populations to use in defining or refining a centroid line or a radius or radii defining a set of normal clusters, and to characterize and compare a test set of cells to the defined set of normal clusters.

This invention discloses a transgenic recombinant immune cell that specifically targets tumors. The recombinant immune cell comprises a chimeric polypeptide and a chimeric antigen receptor; the chimeric polypeptide includes a first extracellular region, a first transmembrane region, and a first intracellular region with HLA-G protein binding activity, wherein the N-terminus of the first transmembrane region is connected to the C-terminus of the first extracellular region, and the N-terminus of the first intracellular region is connected to the C-terminus of the first transmembrane region; the first transmembrane region includes the transmembrane region of the Notch receptor protein from Xenopus laevis; the antigen-chimeric receptor does not have HLA-G protein binding activity. This recombinant immune cell significantly improves the precise recognition of tumor cells by immune cells, reduces off-target effects of cell therapy, and accurately and effectively distinguishes tumor cells from normal cells, providing an effective target and targeting method for the treatment of broad-spectrum tumors (especially solid tumors).

This invention belongs to the field of biomedical technology, specifically relating to a Pt 2+ - Carbon dot@protoporphyrin sonodynamic drug delivery system, its preparation method and application, by loading Pt onto the surface of carbon dots 2+ Modification layer, to obtain Pt 2+ After carbon dots are formed, protoporphyrin is loaded onto them to obtain a carbon dot core with Pt loaded on the carbon dot surface. 2+ Modification layer, in Pt 2+ A sonodynamic drug delivery system with a protoporphyrin-modified layer loaded on the outside of the modified layer can be used in anti-tumor drugs to screen liver cancer cells and normal cells. It has good biocompatibility and significant in vivo sonodynamic anti-tumor effects. It can promote the generation of reactive oxygen species, target and remain in the subcutaneous tumor site in vivo for a long time, increase the mortality rate of cancer cells, and inhibit tumor growth. In a 3D constructed in vitro hepatocellular tumor microenvironment model, this drug delivery system still has superior sonodynamic therapeutic effects.

This invention relates to the field of cell biology, and more particularly to a method for constructing an artificial cell model in vitro based on extracts from Xenopus laevis egg cells. The method includes: mixing cytoplasmic extracts from Xenopus laevis egg cells, demembranous sperm, and tubulin, dispersing the mixture in an oil phase to obtain a reconstructed system; reacting the reconstructed system at 20-24°C for at least 30 minutes, resulting in the formation of a phospholipid bilayer-based cytoplasmic membrane structure around the cell. This invention provides a method for constructing artificial cells by selecting cytoplasmic extracts from Xenopus laevis egg cells, adding specific substances, and reacting under specific conditions to allow the extracts to self-assemble into cell structures in vitro, simultaneously forming a cytoplasmic membrane. The method provided by this invention offers important clues to the origin and evolution of cells, and the resulting artificial cell structures are highly similar to normal cells, possessing significant application value.

Provided are a three-dimensional nonvolatile memory device and a manufacturing method thereof. The three-dimensional nonvolatile memory device includes a substrate including a cell region and an extension region having a stepped structure, a vertical structure on the substrate, a stack structure having an electrode layer and an interlayer insulating layer on the substrate, an isolation insulating layer on the substrate and isolating the electrode layer, and a via wiring region adjacent to the cell region or the extension region and having a via passing through the substrate, wherein the cell region includes a main cell region in which normal cells are arranged and an edge cell region, the isolation insulating layer includes a main isolation insulating layer in the main cell region and an edge isolation insulating layer in the edge cell region, and a lower surface of the main isolation insulating layer is higher than an upper surface of the substrate and has a different depth from a lower surface of the edge isolation insulating layer.

The application discloses a kind of stem cell activity detection culture equipment for treating diabetes, it is related to stem cell culture technical field, including incubator, the incubator inside is provided with culture dish, the culture dish below is provided with alternating magnetic field generator, the inside of the culture dish is placed with stem cell and culture solution, the culture solution belongs to electrolyte solution, alternating current is generated in culture dish when the alternating magnetic field generator starts.This application is separated by the setting of partition ring and piston ring, cooperates alternating magnetic field generator, realizes the separation of normal cell and dead stem cell under the action of centrifugal force, monitoring mechanism cooperates piston ring, detects the cell in the edge of culture dish, recycles dead stem cell using inactivation space, observer can clearly understand the approximate situation of stem cell cultivation in culture dish, the setting of observation mechanism, and cooperate with protective ball and alternating magnetic field generator, reduce stem cell stacking, improve the observation effect of stem cell for researchers.

A somatic mutation detecting apparatus according to the present invention comprises: a memory for storing a program for detecting the somatic mutation; and a processor for executing the program for detecting the somatic mutation, wherein the program for detecting the somatic mutation detects somatic mutation by using a machine learning model, which detects somatic mutation by using, as training data, virtual cancer tissue genome data in which cancer tissue genome data and normal tissue genome data are mixed at different proportions, respectively.

This invention belongs to the field of trastuzumab technology, specifically relating to a Nod2 gene knockout CHO cell line, its preparation method, and its applications. The Nod2 gene in the knockout CHO cells is lost. The CHO cells stably express trastuzumab before Nod2 gene knockout. At the same cell density, the CHO cell line shows a 1.22-1.55-fold increase in trastuzumab expression. This invention knocks out the Nod2 gene in CHO cells using a CRISPR / Cas9 system, and also provides a method for constructing the cell line, a method for producing trastuzumab using the cell line, and applications of the cell line. The Nod2 gene knockout cell line significantly increases trastuzumab expression in suspension culture while effectively reducing the aggregation level of the target protein. Furthermore, the high-yield trastuzumab trait is stably inherited and does not significantly inhibit normal cell growth, providing a new stable platform for efficient trastuzumab production and possessing significant industrial application value.

This application discloses an in vitro reconstructed vaginal mucosa model, its construction method, and its application. The construction method includes an improved culture medium: HVU medium is added to immortalized vaginal epithelial cell line VK2 / E6E7, which is then seeded into Transwell chambers and cultured. The HVU medium on the surface of the culture in the Transwell chambers is aspirated, and the Transwell chambers are raised to the air-liquid interface for air-liquid surface culture. The culture medium is then replaced with HVA medium to obtain the vaginal mucosa model. This method improves the stability of cells during in vitro culture and constructs an in vitro reconstructed vaginal mucosa model with a tissue structure highly similar to human vaginal mucosa (possessing a complete stratified squamous epithelial structure and normal intercellular connections), thereby enhancing the model's physiological functional simulation.

The application discloses a ROS-targeted nano-drug delivery system, which uses a biomimetic hybrid nanovesicle and montmorillonite as a composite carrier and loads ROS-responsive micelles prepared by mixing a PD-L1 antagonistic peptide complex and an RGD complex. The biomimetic hybrid nanovesicle is prepared by modifying a cell-derived nanovesicle with a liposome composed of lecithin, cholesterol and rhamnolipid. The system realizes the synergy of four functions through the EPR effect of the biomimetic hybrid nanovesicle, the active targeting of RGD, the immunomodulation of the PD-L1 antagonistic peptide and the ROS-responsive rupture of the micelles. Experiments show that the system has a significant structural response under a high ROS environment, can quickly disintegrate to release drugs, has high selectivity and high uptake rate for high-ROS tumor cells, has low toxicity to normal cells and good blood compatibility. The system provides an efficient and safe nano-drug delivery platform for the targeted treatment of ROS-related diseases such as tumors.

This invention discloses an intracellular imaging system for simultaneously detecting UDG and miR-375 expression levels and its applications. The intracellular imaging system uses a tetrahedral DNA nanostructure as a carrier, loading a HAT-UDG probe with an on / off conformation, and coupling it with a split CRISPR / Cas12a detection component for recognizing miR-375. The split CRISPR / Cas12a detection component includes at least Cas12a protein, scaffold RNA, spacer RNA / equivalent split crRNA components, and a fluorescent reporter substrate. This invention is the first to perform a logical AND operation between two key indicators: UDG enzyme activity and miR-375 expression level. The system can only ultimately trigger a complete fluorescence signal when both are simultaneously highly expressed. This multi-target synergistic activation design constructs a precise molecular recognition logic gate, enabling extremely accurate differentiation between prostate cancer cells (RV-1) and normal cells (293T), as well as other cancer cells (5637) that highly express UDG, fundamentally avoiding misjudgments caused by fluctuations in a single indicator or non-specific expression, resulting in extremely high imaging specificity.

Provided are an oncolytic virus, a preparation method therefor, the use thereof and a medicine thereof, wherein the genome of the oncolytic virus includes the following exogenous elements: (1) a first expression cassette containing a first promoter and a first interfering RNA expression sequence; (2) a target sequence; and (3) a second expression cassette. The replication of the oncolytic virus is regulated and controlled by exogenous elements inserted into the genome sequence thereof; by means of the regulation and control by the exogenous elements, the oncolytic virus can be selectively replicated in different types of cells, and thus, second cells, that is, target cells (such as tumor cells), can be selectively killed, and first cells, that is, non-target cells (such as normal cells), are not damaged.

This invention discloses a cerium-based metal-organic framework (MOF)-based nanomedicine for multimodal synergistic tumor therapy, its preparation method, and its applications. The nanomedicine is an Au@Ce-MOF@Ce₂S₃ composite nanosystem that can responsively degrade in the acidic tumor microenvironment, simultaneously releasing H₂S gas, Au nanoparticles, and Ce³⁺. The Au nanoparticles possess glucose oxidase-like activity, catalyzing the oxidative decomposition of glucose to achieve starvation therapy and in-situ generation of H₂O₂. Ce³⁺ further catalyzes a Fenton-like reaction in H₂O₂, generating highly reactive hydroxyl radicals (·OH) for chemokinetic therapy. Simultaneously, the released H₂S interferes with cysteine ​​metabolism, depletes glutathione (GSH), and synergistically inhibits GPX4 activity, inducing lipid peroxidation and ferroptosis. This nanosystem achieves highly efficient killing of tumor cells through multimodal synergistic effects of starvation therapy, gas therapy, chemokinetic therapy, and ferroptosis, while exhibiting advantages such as low cytotoxicity to normal cells, good blood compatibility, and high biosafety. This invention provides a novel design strategy for constructing tumor microenvironment-responsive multifunctional nanomedicines, which has promising applications in the fields of efficient, safe, and targeted anti-tumor therapy.

The application relates to the technical field of metal organic complexes, in particular to a chiral Au 16 Metal complex and preparation method and application thereof. By using a specific chiral 1,4-di (dithiocarbamate) -2-methyl piperazine potassium salt ligand, a specific chiral Au 16 Metal complex, 16 Au atoms in the structure of the metal complex form an Au 16 Macrocycle, 16 gold atoms form a polynuclear gold compound, and the chiral Au 16 Drug activity of the metal complex on cancer cells. In in-vitro cell experiments, the chiral Au 16 The metal complex has good in-vitro anticancer activity in different cancer cell lines. Meanwhile, due to the Au-Au bonding, a macrocycle structure is formed, and the chiral Au 16 Cytotoxicity of the metal complex on normal cells.

This invention discloses a VH032-modified phthalocyanine, its preparation method, and its applications. A chemical synthesis method involving amino and carboxyl coupling is employed. The photosensitizer ZnPc and the Von Hippel-Lindau (VHL) ligand VH032 are linked using either no linker or an alkyl or PEG chain as a linker to construct the VH032-modified phthalocyanine. This drug can degrade VHL after light irradiation and, combined with photodynamic therapy (PDT), efficiently kill tumor cells, achieving a phototoxicity index (PI) of 36397. Utilizing the more active regulation of Cyclin Dependent Kinase 2 / 4 (CDK2 / 4) by VHL in bladder cancer tumor tissue, after light irradiation, this compound exhibits a selectivity index (SI) of 749 for killing bladder cancer cells compared to normal cells, achieving selective killing of tumor cells under light conditions and effectively avoiding the risk of damage to adjacent normal tissues during treatment.

This disclosure relates to novel GSPT1 degraders and the use of novel GSPT1 degraders. More specifically, this disclosure relates to a compound represented by formula I, or its stereoisomer, hydrate, solvate, or pharmaceutically acceptable salt, a pharmaceutical composition containing the same for treating disorders of uncontrolled cell proliferation, and a method for treating disorders of uncontrolled cell proliferation by administering the same to a mammal. The compounds relating to this disclosure exhibit high selectivity and sustained degrading activity for GSPT1, excellent pH stability, and low cytotoxicity to normal cells, and therefore have excellent anticancer efficacy and a high therapeutic index. In addition, the compounds relating to this disclosure may exhibit excellent anticancer activity against cancers exhibiting a neuroendocrine phenotype, such as small cell lung cancer (SCLC), neuroendocrine pulmonary cancer (NEC), and neuroendocrine prostate cancer (NEPC).

The purpose of the present invention is to provide a means for selecting subject-derived neoantigens. The above problem is solved by providing a method for selecting a subject-derived neoantigen, said method comprising: a step of acquiring sequence data of a normal cell and a cancer cell derived from a subject, a step of identifying a gene having a genetic mutation specific to the cancer cell, and a step of identifying a peptide based on a wild-type gene corresponding to the gene having the genetic mutation specific to the cancer cell from a major histocompatibility complex (MHC)-presented peptide database, wherein the genetic mutation is a missense mutation, and the peptide based on the wild-type gene corresponding to the gene having the genetic mutation has a wild-type amino acid corresponding to the position of an amino acid mutation due to the genetic mutation.